Targazyme Stock

targazyme.comBioTechFounded: 2005Funding to Date: $2.5MM

Targazyme is a clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine.

Register for Details

For more details on financing and valuation for Targazyme, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Lynnet Koh
Chief Executive Officer, President, Chairman & Co-Founder
Stephen Wolpe Ph.D
Chief Scientific Officer
Bernard Cambou
Chief Business Officer
Lynne Bui MD
Chief Medical Officer & Senior Vice President, Development
Zhongling Feng MD
Associate Chief Medical Officer

Board Members

Alan Lewis Ph.D
Charles Levine
Targazyme
Christopher Calhoun
Targazyme
Kris Narayan
Targazyme
Lynnet Koh
Targazyme
Mark Schwartz Ph.D
Targazyme
Michael LeMaire

Other companies like Targazyme in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM